Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially

Personalis, Inc.

2025-Q1 EPS reported -$0.18 revenue$20,605,000

Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).
Net loss $15.8M ($0.18/share) vs $13.0M ($0.26) in Q1 2024; per-share improved on higher share count.
Clinical test volume 2,184, up 52% from Q4 2024; NeXT Personal data in CRC and breast cancer submitted for Medicare.
Raised $17.8M net from ATM at $5.89/share; cash $185.7M; operations cash use $20.5M.
FY2025 revenue guidance unchanged $80-90M; gross margin raised to 22%-24%; net loss guidance narrowed to ~$83M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.